OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Subscription and Copyright Information	705
Subscription and Copyright Information	616
Advisory Board and Contents	302
Subscription and Copyright Information	291
Subscription and Copyright Information	258
Subscription and Copyright Information	233
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	230
Structural asymmetry in FGF23 signaling	218
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	203
Shearing of surface mucin saps tumor cell strength	196
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	177
Therapeutic inhibition of ferroptosis in neurodegenerative disease	160
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	152
Compstatins: the dawn of clinical C3-targeted complement inhibition	149
Swinging the SWI/SNF complexes for cancer therapy	147
Structural pharmacology and mechanisms of GLP-1R signaling	125
Targeting complement in neurodegeneration: challenges, risks, and strategies	125
Cancer pathogenesis and phase targeting through condensate fragility	123
Direct in vivo CAR T cell engineering	121
Advisory Board and Contents	120
Advisory Board and Contents	118
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	115
Advisory Board and Contents	114
A perspective on psychedelic teratogenicity: the utility of zebrafish models	112
Programmable CAR immunotherapies for neurodegenerative proteinopathies	111

Leveraging human microbiomes for disease prediction and treatment	104
Phenotypic approaches for CNS drugs	102
Engineering ACE2 decoy receptors to combat viral escapability	100
Nemolizumab (Nemluvio®) for prurigo nodularis	99
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	97
HSV-1 as a gene delivery platform for cancer gene therapy	96
Genetically engineered loaded extracellular vesicles for drug delivery	89
Ribosome-directed cancer therapies: the tip of the iceberg?	88
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	86
A deep dive into degrader-induced protein-protein interfaces	82
Optogenetic engineering for precision cancer immunotherapy	80
Mechanistic insights into nitazenes at the μ-opioid receptor	79
Subscription and Copyright Information	79
Engineering early immune resilience in islet transplantation	77
Thriving as members of under-represented groups in pharmacology-related careers	72
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	72
Subscription and Copyright Information	70
Emerging approaches to induce immune tolerance to therapeutic proteins	69
Now you serine, now you don't	67
Subscription and Copyright Information	67
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	65
Bimetallic nanoadjuvants for cancer vaccines	65
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	61
Suzetrigine for moderate to severe acute pain	61
Could dexmedetomidine be repurposed as a glymphatic enhancer?	61
Piezo1: structural pharmacology and mechanotransduction mechanisms	60
The structure, function, and pharmacology of MRGPRs	58
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	57
Autologous, allogeneic, in vivo CAR for autoimmune diseases	54
Molecular glues evolve from serendipity to rational design	53
Advancing non-destructive analysis of 3D printed medicines	52
Targeting metabolic vulnerabilities with advanced delivery systems	48
Advisory Board and Contents	46
The road less traveled: activating an oncogenic kinase	45
The promise of targeted protein degradation approaches	44
Treg-directed cancer immunotherapy beyond immune checkpoints: progress and opportunities	44
Salt-inducible kinases: new players in pulmonary arterial hypertension?	44
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	44
Advisory Board and Contents	43
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	43
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	42
Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance	41
Promising neuroimmune targets and drugs for CNS diseases	41
Advisory Board and Contents	40
Subscription and Copyright Information	40
The end of the beginning in understanding SLC22 polyspecificity	40
Validation of agent-based models of surface receptor oligomerisation	39
Tackling microbial iron homeostasis: novel antimicrobial strategies	39
A novel function of the M2 muscarinic receptor	39
Beyond G protein and arrestin: GRK2-biased β₂AR signaling	39

Monkeypox: potential vaccine development strategies	39
PDE4 modulates muscle signaling in cancer cachexia	38
Chaperones in kinase homeostasis and drug discovery	37
Targeting the assembly of biomolecules: condensate-based drug discovery	37
Vepdegestrant for ESR1-mutated breast cancer	35
Protein acylations in cancer immunity: effects and therapeutic opportunities	35
BTK inhibitors: past, present, and future	34
Artificial intelligence in rare diseases: toward clinical impact	34
Frizzleds act as dynamic pharmacological entities	34
Subscription and Copyright Information	33
Advisory Board and Contents	33
Advisory Board and Contents	33
Recent advances in generative biology for biotherapeutic discovery	32
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	32
Topical difamilast for the treatment of mild-to-moderate atopic dermatitis	32
Biosensors for translatable GPCR bias	32
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	32
Metabolic regulation in normal and leukemic stem cells	32
Demographic diversity in platelet function and response to antiplatelet therapy	32
Eflornithine for treatment of high-risk neuroblastoma	31
GPR35 in host–microbe interaction: Mechanisms and translational prospects	31
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	30
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	30
GPR35: from enigma to therapeutic target	30
Development of PROTACs using computational approaches	29
Targeting plasma membrane cholesterol as a novel anticancer therapy	29
Subscription and Copyright Information	28
Subscription and Copyright Information	28
Tackling chronic kidney disease in diabetic patients with finerenone	28
Subscription and Copyright Information	27
Targeting sensory neuron GPCRs for peripheral neuropathic pain	27
The structure, function, and pharmacology of SK channel family	27
Biologics and cardiac disease: challenges and opportunities	27
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	27
A novel anticancer pharmacological agent targeting mitochondrial complex I	27
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	27
Visceral obesity and HFpEF: targets and therapeutic opportunities	26
Boosting CAR-T cell therapy through vaccine synergy	26
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	25
Neutrophil extracellular traps in wound healing	24
Therapeutic antibodies targeting G protein-coupled receptors	24
Subscription and Copyright Information	24
Recent advancements in vaccine research and development	24
Multitargeting neuroimmune pathways: novel candidates for chronic pain relief	24
Taming PRMT5–adaptor protein interactions	23
ECM stiffness and epigenetics in organ fibrosis	23
WEE-family kinases in cancer: synthetic lethal interactions and drug discovery	22
Subscription and Copyright Information	22
Circadian biology to advance therapeutics for mood disorders	22
The ABCs of psychedelics: a preclinical roadmap for drug discovery	21
GABAA receptors as targets for treating affective and cognitive symptoms of depression	21
Chronobiomaterials for circadian-aligned brain therapeutics	21
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	21
Targeting competitive Fe–S regulation to treat Friedreich’s ataxia	21
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	20
The structure and function of YTHDF epitranscriptomic m6A readers	20
NLRP3 and pyroptosis blockers for treating inflammatory diseases	20
Challenges and opportunities associated with rare-variant pharmacogenomics	20
August 2026 issue first authors	20
Advisory Board and Contents	19
Potential for targeting small heat shock protein modifications	19
Subscription and Copyright Information	19
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	19
Targeting peptide–HLA complexes for precision immunotherapy	19
GPCR-dependent and -independent arrestin signaling	18
Drugging cold-response networks for neuroprotection	18
Subscription and Copyright Information	18
Glymphatic-stagnated edema induced by traumatic brain injury	18
Targeted protein degrader development for cancer: advances, challenges, and opportunities	18
Advisory Board and Contents	18
STING-mediated cancer immunotherapy: emerging modalities and beyond	18
Odorant receptors as potential drug targets	18
β-Arrestins and disease-linked variants: opportunities for targeted modulation	18
Induced proximity for dephosphorylation	18